眼部检测可快速诊断帕金森症

2016-08-25 佚名 生物谷

(图片摘自www.sciencealert.com)科学家们最近发现大鼠的视网膜变化能够作为帕金森症的发病前预测指标。如果该方法同样适用于人体,那么将会提供一类新型的廉价且无创的帕金森早期诊断方法。 该技术仅仅需要一台眼科医师常用的仪器,这意味着它能够同样对帕金森症患者进行诊断与治疗效果的鉴定。  “这可能是帕金森症早期诊断与治疗领域最具革命性的突破”,该研究的首席作者,来自伦敦


(图片摘自www.sciencealert.com)

科学家们最近发现大鼠的视网膜变化能够作为帕金森症的发病前预测指标。如果该方法同样适用于人体,那么将会提供一类新型的廉价且无创的帕金森早期诊断方法。

该技术仅仅需要一台眼科医师常用的仪器,这意味着它能够同样对帕金森症患者进行诊断与治疗效果的鉴定。

 “这可能是帕金森症早期诊断与治疗领域最具革命性的突破”,该研究的首席作者,来自伦敦学院大学的Francesca Cordeiro说道。

 “这些检测意味着我们可能能够早患者病情未恶化之前进行有效的诊断与针对性的治疗”。

帕金森症是世界上最严重的神经疾病之一,平均每500个人中就有一名帕金森症患者。目前,帕金森症的最终诊断只能通过神经学的方法,这一方法十分复杂,需要许多不同的单项检测得以实现。

而帕金森症由于发病早期的症状十分微小,因此常常容易被忽视。最终,许多患者直到病情恶化到十分严重的程度才知晓,而此时大脑中至少70的多巴胺分泌细胞都受到了损坏。

因此,帕金森症的早期诊断被认为是能够改变这一现状的最有效的方法. 

该新型的技术是通过从眼球的背部打光,并观察视网膜多少(RGC)细胞开始死亡。同时,也能够观察到该区域的肿胀情况。

在该研究中,研究者们对帕金森症早期的大鼠进行RGC细胞凋亡的检测并观察该区域的肿胀程度。结果显示,在帕金森症病发之前60天前就能够通过该方法得到明显的检测结果。

进一步,作者对早期检测的大鼠进行针对性的治疗,并观察早期的治疗是否有一定的优势。他们给予大鼠一类叫做rosiglitazone的治疗糖尿病的药物,结果显示,该药物的之咯啊哦能够有效缓解神经细胞的损伤。

如上所述,这些结果都需要在人体水平进行验证,之后才可能应用于临床。不过,研究者们认为他们的结果应该十分可信,值得进行临床试验。

相关结果发表在《Acta Neuropathologica Communications》杂志上。

原始出处

Eduardo Maria Normando, Benjamin Michael Davis, Lies De Groef, Shereen Nizari, Lisa A. Turner, Nivedita Ravindran, Milena Pahlitzsch, Jonathan Brenton, Giulia Malaguarnera, Li Guo, Satyanarayana Somavarapu and Maria Francesca CordeiroEmail author.The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.Acta Neuropathologica Communications.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1776050, encodeId=06e01e76050c1, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Jul 27 23:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109965, encodeId=ea0d10996588, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Sep 02 23:58:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106145, encodeId=3e11106145e3, content=动物实验结果,期待人体临床研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Aug 28 09:41:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518870, encodeId=db9a15188e06f, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Sat Aug 27 10:55:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104367, encodeId=f09d10436e08, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104377, encodeId=650f1043e72b, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104329, encodeId=d26a10432966, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:57:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2017-07-27 huiwelcome
  2. [GetPortalCommentsPageByObjectIdResponse(id=1776050, encodeId=06e01e76050c1, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Jul 27 23:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109965, encodeId=ea0d10996588, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Sep 02 23:58:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106145, encodeId=3e11106145e3, content=动物实验结果,期待人体临床研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Aug 28 09:41:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518870, encodeId=db9a15188e06f, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Sat Aug 27 10:55:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104367, encodeId=f09d10436e08, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104377, encodeId=650f1043e72b, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104329, encodeId=d26a10432966, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:57:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-09-02 李东泽

    很好,不错,以后会多学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1776050, encodeId=06e01e76050c1, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Jul 27 23:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109965, encodeId=ea0d10996588, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Sep 02 23:58:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106145, encodeId=3e11106145e3, content=动物实验结果,期待人体临床研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Aug 28 09:41:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518870, encodeId=db9a15188e06f, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Sat Aug 27 10:55:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104367, encodeId=f09d10436e08, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104377, encodeId=650f1043e72b, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104329, encodeId=d26a10432966, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:57:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-28 meiliwuxian

    动物实验结果,期待人体临床研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1776050, encodeId=06e01e76050c1, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Jul 27 23:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109965, encodeId=ea0d10996588, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Sep 02 23:58:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106145, encodeId=3e11106145e3, content=动物实验结果,期待人体临床研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Aug 28 09:41:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518870, encodeId=db9a15188e06f, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Sat Aug 27 10:55:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104367, encodeId=f09d10436e08, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104377, encodeId=650f1043e72b, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104329, encodeId=d26a10432966, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:57:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-27 howi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1776050, encodeId=06e01e76050c1, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Jul 27 23:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109965, encodeId=ea0d10996588, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Sep 02 23:58:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106145, encodeId=3e11106145e3, content=动物实验结果,期待人体临床研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Aug 28 09:41:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518870, encodeId=db9a15188e06f, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Sat Aug 27 10:55:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104367, encodeId=f09d10436e08, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104377, encodeId=650f1043e72b, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104329, encodeId=d26a10432966, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:57:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-26 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1776050, encodeId=06e01e76050c1, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Jul 27 23:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109965, encodeId=ea0d10996588, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Sep 02 23:58:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106145, encodeId=3e11106145e3, content=动物实验结果,期待人体临床研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Aug 28 09:41:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518870, encodeId=db9a15188e06f, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Sat Aug 27 10:55:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104367, encodeId=f09d10436e08, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104377, encodeId=650f1043e72b, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104329, encodeId=d26a10432966, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:57:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-26 1dd8a7c5m95(暂无匿称)

    学习了,赞一个!!!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1776050, encodeId=06e01e76050c1, content=<a href='/topic/show?id=508ae2913d6' target=_blank style='color:#2F92EE;'>#眼部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72913, encryptionId=508ae2913d6, topicName=眼部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=126338864246, createdName=huiwelcome, createdTime=Thu Jul 27 23:55:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109965, encodeId=ea0d10996588, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Sep 02 23:58:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=106145, encodeId=3e11106145e3, content=动物实验结果,期待人体临床研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Sun Aug 28 09:41:00 CST 2016, time=2016-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518870, encodeId=db9a15188e06f, content=<a href='/topic/show?id=2ad14853585' target=_blank style='color:#2F92EE;'>#帕金森症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48535, encryptionId=2ad14853585, topicName=帕金森症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b6811200125, createdName=howi, createdTime=Sat Aug 27 10:55:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104367, encodeId=f09d10436e08, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104377, encodeId=650f1043e72b, content=学习了,赞一个!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Fri Aug 26 10:59:00 CST 2016, time=2016-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=104329, encodeId=d26a10432966, content=这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Aug 26 10:57:00 CST 2016, time=2016-08-26, status=1, ipAttribution=)]
    2016-08-26 李东泽

    这篇资讯写的真好,带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

相关资讯

盘点:拳王阿里去世:头部受伤会导致帕金森症么?

  图片来自:http://www.boxinginsider.com/ 世界拳击冠军穆罕默德·阿里在上周五(6月3日)在美国亚利桑那州凤凰城的医院去世,享年74岁。他的葬礼将在他的故乡,美国肯塔基州的路易维尔举行。这位出生在上世纪四十年代的美国黑人,曾连续三次获得世界重量级拳击冠军,并积极参与社会活动,广受世人尊敬。 在拳王阿里去世前,他曾长期遭受帕金森综合征的折磨,时间长达

芹黄素可用于治疗神经退行性疾病!

研究人员认为,芹黄素(在红辣椒、洋甘菊和许多其他植物和草药中发现)可用于治疗许多神经退行性疾病,包括老年痴呆症、帕金森症和精神分裂症等。

Hum Genet:人造“中脑” 或有助研究帕金森症

新加坡的科学家们说,他们已经创造出世界上第一个人造微型“中脑”,即人脑包括视力,听力和活动控制的部分。包括帕金森氏症在内的脑部变性疾病损坏的就是这部分脑功能。 以新加坡为研究基地的这个科研小组称,他们的发现将帮助找到治疗上述疾病患者的新方法。 这个创造出来的标本只有两毫米宽,是大脑的信息高速公路中脑的一个微缩版本。科学家们说,创造了带有神经黑色素的微缩中脑版本。 这种神经黑色

针灸治疗帕金森症?中国科学家揭示其分子机制

中国科学院上海应用物理研究所物理生物学研究室通过与上海中医药大学针灸经络研究所、针灸推拿学院以及龙华医院针灸科等单位合作,在帕金森症(Pakinson's disease)小鼠模型上探索了针灸作用的分子机制。研究发现,针刺小鼠腿部的阳陵泉穴可以通过非mTOR依赖途径调节脑内多巴胺能神经元的自噬通路,恢复其受损的自噬(autophagy)水平,清除α-突触核蛋白(α-synuclein)在脑内的

科学家发明人造“中脑” 或有助研究帕金森症

据外媒报道,新加坡的科学家们说,他们已经创造出世界上第一个人造微型“中脑”,即人脑包括视力,听力和活动控制的部分。包括帕金森氏症在内的脑部变性疾病损坏的就是这部分脑功能。 以新加坡为研究基地的这个科研小组称,他们的发现将帮助找到治疗上述疾病患者的新方法。 这个创造出来的标本只有两毫米宽,是大脑的信息高速公路中脑的一个微缩版本。科学家们说,创造了带有神经黑色素的微缩中脑版本。 这种神经黑色素是

JAMA Neurol:帕金森症患者早期体重减轻可能预示着病情加重

一项由马萨诸塞州总医院(MGH)领导的调查研究发现帕金森病患者早期体重下降与更快的疾病进展有关。虽然研究结果显示帕金森病患者体重下降是很常见的—这是JAMA Neurology在三月份时发表的一项研究—疾病过程中体重下降可能意味着更严重的一种神经退行性疾病。“我想我们可以看到这种疾病的几种亚型,”MGH神经病学和神经临床研究所,JAMA神经病学论文的通讯作者,医学博士Anne-Marie Will